Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 6/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10387231 | 0.73 | ADRB2 (0.35) | ADRB1ADRB2LMNATSHRHTR1A | |
| SCHEMBL10254376 | 0.70 | NUDT1 (0.35) | ADRB1ADRB2TSHRKDM4ECYP1A2 | |
| SCHEMBL3136060 | 0.69 | ADRB2 (0.42) | ADRB1ADRB2LMNATSHRKDM4E | |
| SCHEMBL12929941 | 0.68 | ADRB2 (0.37) | ADRB1ADRB2TSHRKDM4ECYP1A2 | |
| SCHEMBL10387739 | 0.68 | MEN1 (0.38) | ADRB1ADRB2TSHRKDM4ECYP1A2 | |
| SCHEMBL3134510 | 0.66 | PDCD1LG2 (0.43) | ADRB1ADRB2TSHRKDM4ECYP1A2 | |
| SCHEMBL11248023 | 0.65 | ADRB1 (0.39) | ADRB1ADRB2LMNATSHRHTR1A | |
| SCHEMBL13950563 | 0.63 | ADRB2 (0.46) | ADRB1ADRB2KDM4ECYP2D6NFKB1 | |
| Methyl Alcohol SCHEMBL3127423 | 0.63 | ADRB2 (0.51) | ADRB1ADRB2LMNATSHRHTR1A | |
| SCHEMBL594098 | 0.61 | ADRB2 (0.44) | ADRB1ADRB2LMNATSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190125699-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | CIPHER PHARMACEUTICALS INC. (CA) | 2019-05-02 | — | — | US | disclosed |
| US-9907765-B2 | Treatment of connective tissue diseases of the skin | CIPHER PHARMACEUTICALS INC. (CA) | 2018-03-06 | — | — | US | disclosed |
| US-20170157068-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ASTION PHARMA A/S (DK) | 2017-06-08 | — | — | US | disclosed |
| US-20130237607-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ASTION DEVELOPMENT A/S (DK) | 2013-09-12 | — | — | US | disclosed |
| US-8426475-B2 | Treatment of connective tissue diseases of the skin | ASTION DEVELOPMENT A/S (DK) | 2013-04-23 | — | — | US | disclosed |
| EP-1719507-B1 | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin | ASTION DEV AS (DK) | 2010-07-14 | — | — | EP | disclosed |
| WO-2006108424-A9 | BETA-2 ADRENOCEPTOR AGONISTS FOR TREATING CONNECTIVE TISSUE DISEASES OF THE SKIN | ASTION DEV AS (DK) | 2007-08-09 | — | — | WO | disclosed |
| EP-1719507-A1 | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin | Astion Development A/S (DK) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006108424-A2 | BETA-2 ADRENOCEPTOR AGONISTS FOR TREATING CONNECTIVE TISSUE DISEASES OF THE SKIN | ASTION PHARMA A/S (DK) | 2006-10-19 | — | — | WO | disclosed |
| US-20060235048-A1 | Treatment of connective tissue diseases of the skin | ASTION DEVELOPMENT A/S | 2006-10-19 | — | — | US | disclosed |
| US-4906781-A | Method for the preparation of 4'-(substituted)-amino-2-(substituted) amino-3',5'-dichloroacetophenone and salts thereof | AMERICAN CYANAMID COMPANY (US) | 1990-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237607-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ADRB2, ADRB1, ADRA2A | ADRB1 2/4885ADRB2 1/4885LMNA 391/4885 |
| US-20060235048-A1 | Treatment of connective tissue diseases of the skin | ADRB2, ADRB1, ADRA2A | ADRB1 2/4885ADRB2 1/4885LMNA 391/4885 |
| US-20170157068-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ADRB2, ADRB1, ADRA2A | ADRB1 2/4885ADRB2 1/4885LMNA 391/4885 |
| US-20190125699-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ADRB2, ADRB1, ADRA2A | ADRB1 2/4885ADRB2 1/4885LMNA 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.